Your browser doesn't support javascript.
loading
Brain Tumor Radiogenomic Classification of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning.
Sakly, Houneida; Said, Mourad; Seekins, Jayne; Guetari, Ramzi; Kraiem, Naoufel; Marzougui, Mehrez.
Afiliação
  • Sakly H; RIADI Laboratory, ENSI, Manouba University, Campus Universitaire de La Manouba, La Manouba, Tunisia.
  • Said M; Radiology and Medical Imaging Unit, International Center Carthage Medical-Monastir, Monastir, Tunisia.
  • Seekins J; Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Guetari R; SERCOM Laboratory, Polytechnic School of Tunisia, University of Carthage, La Marsa, Tunisia.
  • Kraiem N; RIADI Laboratory, ENSI, Manouba University, Campus Universitaire de La Manouba, La Manouba, Tunisia.
  • Marzougui M; College of Computer Science, King Khalid University, Abha, Saudi Arabia.
Cancer Control ; 30: 10732748231169149, 2023.
Article em En | MEDLINE | ID: mdl-37078100
ABSTRACT
Artificial Intelligence (AI) is the subject of a challenge and attention in the field of oncology and raises many promises for preventive diagnosis, but also fears, some of which are based on highly speculative visions for the classification and detection of tumors. A brain tumor that is malignant is a life-threatening disorder. Glioblastoma is the most prevalent kind of adult brain cancer and the 1 with the poorest prognosis, with a median survival time of less than a year. The presence of O6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation, a particular genetic sequence seen in tumors, has been proven to be a positive prognostic indicator and a significant predictor of recurrence.This strong revival of interest in AI is modeled in particular to major technological advances which have significantly increased the performance of the predicted model for medical decision support. Establishing reliable forecasts remains a significant challenge for electronic health records (EHRs). By enhancing clinical practice, precision medicine promises to improve healthcare delivery. The goal is to produce improved prognosis, diagnosis, and therapy through evidence-based sub stratification of patients, transforming established clinical pathways to optimize care for each patient's individual requirements. The abundance of today's healthcare data, dubbed "big data," provides great resources for new knowledge discovery, potentially advancing precision treatment. The latter necessitates multidisciplinary initiatives that will use the knowledge, skills, and medical data of newly established organizations with diverse backgrounds and expertise.The aim of this paper is to use magnetic resonance imaging (MRI) images to train and evaluate your model to detect the presence of MGMT promoter methylation in this competition to predict the genetic subtype of glioblastoma based transfer learning. Our objective is to emphasize the basic problems in the developing disciplines of radiomics and radiogenomics, as well as to illustrate the computational challenges from the perspective of big data analytics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Glioma Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Cancer Control Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Tunísia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Glioma Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Cancer Control Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Tunísia